🇺🇸 FDA
Pipeline program

Mavodelpar

REN001-201

Phase 2 small_molecule completed

Quick answer

Mavodelpar for Primary Mitochondrial Myopathy is a Phase 2 program (small_molecule) at OnKure Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
OnKure Therapeutics
Indication
Primary Mitochondrial Myopathy
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials